Producer
Urenco/ENRICHMENT TECHNOLOGY (Stable Isotopes)
European uranium enrichment company (UK/Netherlands/Germany/US joint venture) that also produces stable isotopes using centrifuge technology. The same centrifuge cascade technology used for uranium enrichment at Urenco's Capenhurst (UK), Gronau (Germany), and Almelo (Netherlands) sites is applicable to stable isotope separation. Urenco has explored stable isotope production as a commercial adjunct to its nuclear fuel cycle business.
0
Inputs supplied
0
Goods downstream
0
Facilities
0
Stories
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Medical Imaging Isotopes
45%Industrial & Research Isotopes
30%Specialty Gas Isotopes
15%Isotope Separation Services
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2022
URENCO Stable Isotopes is a business unit of URENCO Group — the Anglo-Dutch-German uranium enrichment consortium established in 1971 through the Treaty of Almelo to provide enriched uranium fuel for European nuclear power plants. URENCO operates gas centrifuge enrichment plants in the Netherlands (Almelo), Germany (Gronau), the UK (Capenhurst), and USA (Eunice, New Mexico). The same centrifuge technology that separates uranium isotopes (U-235 from U-238 using uranium hexafluoride gas) can, with appropriate modifications, separate stable isotopes of other elements by exploiting the same mass-difference-driven differential centrifugal separation. URENCO Stable Isotopes applies this centrifuge expertise to produce enriched stable isotopes for medical, industrial, and research use — most significantly molybdenum-100 (Mo-100), which is the target material used to produce technetium-99m through neutron bombardment in reactors. Tc-99m is the most widely used medical imaging radioisotope in nuclear medicine — approximately 40 million procedures per year globally depend on it for bone scans, cardiac imaging, and cancer staging. The supply chain for the world's most-used medical imaging isotope thus includes a nuclear enrichment consortium whose primary identity is making fuel for nuclear power stations. This dual-use connection between civilian nuclear fuel enrichment and medical imaging supply chains is one of the least visible in global healthcare infrastructure.
URENCO Group ↗